GHRS Stock Forecast & Price Target

GH Research is viewed positively because GH001 has shown unusually strong Phase IIb efficacy in treatment-resistant depression, including a -15.5 point placebo-adjusted MADRS reduction at Day 8, 57.5% remission at Day 8 versus 0% on placebo, and 73% remission at 6 months with retreatments. The investment case is strengthened by July 2026 FDA written feedback that the CMC and proprietary aerosol delivery device plans appear Phase III ready, which removes two major execution overhangs and supports the company’s stated path to a late-2026 pivotal start. Confidence is further reinforced by high-profile JAMA Psychiatry publication, growing investigator interest in new indications, and the potential for a differentiated session-economics profile that could resemble Spravato without repeated visits.

GH Research is exposed to substantial binary risk because its lead asset GH001 remains under an FDA clinical hold, and even if that hold is lifted, the Phase III study may fail to reproduce earlier efficacy or may be derailed by safety, tolerability, or device-manufacturing issues. The company’s commercialization path is also uncertain, as the DEA may not reschedule mebufotenin, competitors could erode market share, and management may still need additional financing despite having about $362.7MM in cash, cash equivalents, and marketable securities as of June 30, 2026. In 2Q26, R&D rose to $12.4MM and the net loss was $15.1MM, underscoring a cash-burning clinical-stage profile with no diversified revenue base beyond research and development.